Jacobs Journal of Bone Marrow and Stem Cell Research
Predictive Factors for the Outcome of Salvage Autologous Stem Cell Transplant in patient with Relapsed Multiple Myeloma
Published on: 2015-10-02
Background: There is no clear standard of care for patients with multiple myeloma whose disease has relapsed after a prior autologous SCT. Limited data are available regarding the value of salvage auto-SCT, and the factors that determine the outcome have not been well described. Methods: We retrospectively reviewed our experience at Saskatoon Cancer Center with salvage auto-SCT for relapsed multiple myeloma, looking at the outcome and the determining variables that could affect this outcome. Thirty three patients had received a salvage auto-SCT at our institution between; February 2000 to February 2012. Results: Median age at salvage auto-SCT was 60 years (range; 46-71). Median time to relapse after the first auto-SCT was 32 months. Only 30% of the patients received more than 2 lines prior to salvage auto-SCT. Overall response at day 100 after salvage auto-SCT was 93 % and non relapse mortality was 3 %. With a median follow up of 24 months, the median progression free survival (PFS) was 27 months and the median overall survival (OS) was 36 months. Patients who had received Conclusion: Salvage auto-SCT is a safe and effective alternative therapy for patients with relapsed multiple myeloma. Patients received several lines of therapy and their disease progressed in less than 2 years from the initial SCT are unlikely to benefit significantly. Therefore, salvage auto-SCT should be considered as appropriate option for selected patients with relapsed multiple myeloma.